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Background: The apoptosis inhibitor-5 (API5), anti-apoptosis protein, is considered a key molecule in the tumor
progression and malignant phenotype of tumor cells. Here, we investigated API5 expression in cervical cancer, its
clinical significance, and its relationship with phosphorylated extracellular signal-regulated kinase 1 and 2 (pERK1/2)
in development and progression of cervical cancer.
Methods: API5 effects on cell growth were assessed in cervical cancer cell lines. API5 and pERK1/2
immunohistochemical staining were performed on a cervical cancer tissue microarray consisting of 173 primary
cervical cancers, 306 cervical intraepithelial neoplasias (CINs), and 429 matched normal tissues.
Results: API5 overexpression promoted cell proliferation and colony formation in CaSki cells, whereas API5
knockdown inhibited the both properties in HeLa cells. Immunohistochemical staining showed that API5 expression
increased during the normal to tumor transition of cervical carcinoma (P < 0.001), and this increased expression was
significantly associated with tumor stage (P = 0.004), tumor grade (P < 0.001), and chemo-radiation response
(P = 0.004). API5 expression levels were positively associated with pERK1/2 in cervical cancer (P < 0.001) and high
grade CIN (P = 0.031). In multivariate analysis, API5+ (P = 0.039) and combined API5+/pERK1/2+ (P = 0.032) were
independent prognostic factors for overall survival.
Conclusions: API5 expression is associated with pERK1/2 in a subset of cervical cancer patients and its expression
predicts poor overall survival, supporting that API5 may be a promising novel target for therapeutic interventions.
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Cervical cancer is the second most common cancer in
women worldwide [1]. Optimal treatment of early-stage
cervical cancer is either radical surgery or radiotherapy.
However, effective treatment options for patients with lo-
cally advanced cervical cancer are limited [2]. As 99% of
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with high-risk subtypes of human papillomavirus (HPV)
[3]. HPV oncoproteins E5, E6 and E7 are the primary viral
factors attributed to the immortalization and malignant
transformation of cervical cells. They present growth-
stimulating and transforming properties [4]. HPV onco-
gene subtype, E6 and E7, interfere with cellular functions
of tumor suppressor proteins and extend the proliferative
capacity of infected cells by blocking apoptosis [5].
Apoptosis, also known as programmed cell death,
plays a crucial role in development, morphogenesis,
normal cell turnover and immune system function [6].
Acquired resistance to apoptosis is a well-known hall-
mark of cancer and contributes to tumorigenesis and
the malignant phenotype [7]. Extracellular signal-regulated. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vated protein kinase (MAPKs), mediates cell proliferation.
The activation of ERK1/2 induces metaplasia and develop-
ment of tumors via cell cycle arrest and apoptosis inhib-
ition [8,9].
Many oncogenes and tumor suppressor genes have been
discovered and implicated in the regulation of apoptosis.
Among these anti-apoptotic proteins, apoptosis inhibitor-
5 (API5), also called anti-apoptosis clone 11 (AAC11), or
fibroblast growth factor-2-interacting factor (FIF), is a nu-
clear protein. API5 expression has been shown to prevent
apoptosis after growth factor deprivation [10]. The mech-
anism by which API5 prevents apoptosis is poorly under-
stood, but Morris et al. recently showed that its anti-
apoptotic action appears to be mediated by the negative
regulation of transcription factor E2F1-induced apoptosis
[11]. Furthermore, a recent study revealed that API5
contributes to E2F1 transcriptional activation of cell cycle-
associated genes [12]. API5 has been reported to be up-
regulated in multiple cancer cell lines, some metastatic
tumor within lymph node tissues, and B cell chronic
lymphoid leukemia [10,11,13-15]. However, there is no
clear evidence showing API5 role in tumor progression of
cervical cancer. Immune escape has been demonstrated as
important in tumor progression especially in virus induced
tumor such as cervical cancer. In this context, our recent
study showed that API 5 acts as an immune escape gene
by rendering tumor cells resistant to apoptosis triggered
by tumor antigen-specific T cells. This effect was associ-
ated with pERK-dependent degradation of a pro-apoptotic
molecule, BIM [16]. In this report, we aimed at investigat-
ing the clinical significance of API5 and its relationship
with phosphorylated ERK1/2 (pERK1/2) in development
and progression of cervical cancer.
Methods
Patients and tumor samples
In this study, 173 cervical cancer and 306 cervical intrae-
pithelial neoplasia (CIN) cases were prospectively col-
lected from patients who enrolled in Gangnam Severance
Hospital, Yonsei University College of Medicine from
March 1996 to March 2010, and received primary surgery
during that time. All tumor tissues were histologically
reviewed and only specimens with sufficient presence of
tumor cells were included for tissue microarray (TMA)
construction. Cervical cancer patients were clinically staged
according to the International Federation of Gynecology
and Obstetrics (FIGO) staging system. The treatment of
cervical cancer consisted of radical hysterectomy with
pelvic lymph node dissection via laparotomy for FIGO
stage I/II. Adjuvant radiotherapy or platinum-based
concurrent chemo-radiation was performed in cases
with increased risk of recurrent disease, such as positive
resection margins, positive lymph nodes, or parametrialinvolvement. Chemo-radiation therapy consisted of 40 mg/
m2 cisplatin i.v. once a week for 6 weeks concomitantly
with external pelvic and intracavitary radiation. For FIGO
stage III/IV cervical cancer primary chemo-radiation ther-
apy was generally recommended. Clinicopathologic factors
including age, Hybrid Capture® 2 (HC2) result, surgical
procedure, chemo-radiation response, survival time, and
survival status were obtained by reviewing medical records
and pathology reports. Response to therapy was assessed
according to Response Evaluation Criteria in Solid Tumors
(RECIST; version 1.0), either by computed tomography or
magnetic resonance imaging [17]. Chemo-radiation re-
sponse was determined by locoregional recurrence with a
follow-up time of at least 2 years. Tissue samples were col-
lected from patients who had signed informed consent
forms, which was approved by the Institutional Review
Boards of Gangnam Severance Hospital. This study was
additionally approved by the Office of Human Subjects Re-
search at the National Institute of Health.
Plasmid construction
For the generation of the pEGFP-human API5 (hAPI5)
constructs, the DNA fragments encoding hAPI5 were amp-
lified from cDNAs of CUMC6 tumor cells by PCR using a
set of primers: 5′-GCAGATCTATGCCGACAGTAGAG
GAGCT-3′ and 5′-GCGAATTCCTACTTCCCCTGAAG
GTC-3′. The amplified DNAs were subsequently cloned
into the Bgl II/EcoR I sites of pEGFP-C1 (Clontech, Moun-
tain View, CA). Plasmid constructs were confirmed by
DNA sequencing. The nucleotide sequences were deter-
mined using the BigDye Terminator Cycle Sequencing
Ready Reaction Kit (Perkin Elmer Biosystems, Foster City,
CA) and an ABI PRISM 377 DNA sequencer.
Western blotting
A total of 5 × 105 cells were used as described previously
[18,19]. Equal amounts of nuclear protein and cytosol pro-
tein were solubilized in Laemmli buffer (62.5 mM Tris/
HCL pH 6.8, 10% glycerol, 2% SDS, 5% mercaptoethanol
and 0.00625% bromophenol blue), boiled for 5 min, and
then separated by 12% polyacrylamide gel electrophoresis
and transferred to nitrocellulose membranes. The mem-
branes were probed with primary antibodies of API5
(Sigma-Aldrich, St. Louis, MO; clone# 1C2, 1:250) or
GAPDH (Chemicon International, Temecula, CA; clone
no. 6C5, 1:5000) in Tris-buffered saline (TBS)-T contain-
ing 5% BSA (Sigma-Aldrich) at 4°C overnight, followed by
3 washes in TBST, 5 min per wash. The membranes were
incubated with the appropriate secondary antibodies for
1 hr at room temperature. Immunoreactive bands were
visualized by an enhanced chemiluminescence reaction
(ECL, Elpis Biotech, Daejeon, Korea). To observe the cel-
lular localization of API5, HeLa cells were subjected to
fractionation using a commercial kit (Nuclear/Cytosol
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ing to the manufacturer's instructions.
Immunofluorescence
In order to examine the cellular localization of API5, HeLa
cells were cultured on 2-well Laboratory-Tek tissue culture
chamber slides (BD Falcon, Bedford, MA) and transfected
with 0.4 μg of pEGFP-hAPI5 using Lipofectamine™2000
(Invitrogen, Carlsbad, CA) according to manufacturer's
protocol, and incubated for 24 hr. The transfected cells
were fixed and permeable with Cytofix/Cytoperm (BD bio-
sciences, San Diego, CA) for 20 min at 4°C. After washing
in 1× Perm-wash buffer and counterstained nuclear with
DAPI, localization of API5 was demonstrated under a con-
focal laser scanning microscope (ZEISS LSM700, Carl
Zeiss, Oberkochen, Germany).
Establishment of stable cell lines
CaSki, HeLa, and human embryonic kidney 293 (HEK
293) were obtained from the American Type Culture
Collection (ATCC, Manassas, VA). To generate pcDNA3-
API5 plasmid, DNA fragments encoding API5 were amp-
lified from cDNAs of CUMC6 tumor cells by PCR and
inserted into Not I site of pcDNA3 vector. Stable trans-
fected lines were generated by transfecting no insert
(pcDNA3) and pdDNA3-API5 vectors, selected and main-
tained in the presence of appropriate concentrations of
Zeocin™ (Invitrogen).
In vitro transfection of siRNAs
Synthetic small interfering RNA (siRNA) specific for Gfp
or API5 was purchased from Invitrogen; Non-specific
GFP, 5′-GCAUCAAGGUGAACUUCAA-3′ (sense), 5′-
UUGA- AGUUCACCUUGAUGC-3′ (antisense); API5,
5′-UUACUGUGCUCUUAUAAGGAGG-3′ (sense), 5′-
CCUCCUUCUUAUAAGAGCACAGUAA-3′ (antisense).
HeLa cells (5 × 105 cells/well on 6-well dish) were trans-
fected with 300 pmol of the synthesized siRNAs using
Lipofectamine 2000 (Invitrogen) according to the man-
ufacturer’s instructions. RNAi was maintained 10–14
days after transfection of the siRNAs [18].
Colony formation assay
The stable cell lines and siRNA transfected cells (500
cells/well) were plated onto 6 well tissue culture dishes
and incubated for 2 weeks to allow colonies to develop.
Media (4 ml/well) was replaced every 7 days. Colonies
were stained with crystal violet (0.5% in methanol,
Sigma-Aldrich) for 10 min, and washed with de-ionized
water to remove excess stain. Stained colonies of diam-
eter 1 mm were counted manually from microscopic im-
ages. Each colony formation assay was carried out in
triplicate and repeated three times.Tissue microarray construction
TMAs were constructed from 479 formalin-fixed, paraffin-
embedded tissue specimens, including 429 nonadjacent
normal epithelial tissues. Some of the paraffin blocks were
provided by the Korea Gynecologic Cancer Bank through
Bio & Medical Technology Development Program of the
Ministry of Education, Science and Technology, Korea.
Briefly, hematoxylin and eosin (H&E) stained full-face sec-
tions of all cases were reviewed by an institutional patholo-
gist to define representative tumor areas. Four 1.0 mm
diameter tissue cores, consisting of matched tumor speci-
men and normal epithelial tissues, were retrieved from
formalin-fixed, paraffin-embedded tissue blocks and
arrayed on a 38 × 25 mm recipient paraffin block using a
manual tissue arrayer MTA-1 (Beecher Instruments Inc.,
Silver Spring, MD). Sections were cut at 5 μm with a
microtome and placed on charged glass slides. The pres-
ence of tumor tissues on the sections was verified by H&E
staining.
Immunohistochemical staining and scoring
The TMA sections were deparaffinized and rehydrated
through xylenes and descending gradient alcohol. All
slides were quenched for 10 min in 3% H2O2 to block for
endogenous peroxidase. Heat-induced antigens retrieval
was done for 10 min in an antigen retrieval buffer of pH 6
(Dako, Carpinteria, CA) using a steam pressure cooker
(Pascal, Dako). Sections were then treated with protein
blocks (Dako) for 20 min to block non-specific staining.
The slides were then stained with anti-API5 mouse mono-
clonal antibody (Sigma-Aldrich, clone no. 1C2, 1:250 for
2 hr at room temperature) and rabbit anti-pERK1/2
monoclonal antibody (Cell Signaling, Danvers, MA; clone
no. 20G11, 1:150 for 2 hr at room temperature) in a Dako
Autostainer Plus (Dako). The antigen-antibody reaction
was detected with Dako EnVision +Dual Link System-
HRP (Dako) and DAB+ (3, 3′-Diaminobenzidine; Dako).
After counterstaining in hematoxylin, slides were mounted
manually and scanned using a ScanScope CS digital scan-
ner (Aperio Technologies, Vista, CA).
The API5 and pERK1/2 staining results were scored
based on (a) intensity [categorized as 0 (absent), 1 (weak),
2 (moderate), or 3 (strong)] and (b) the percentage of posi-
tively stained epithelial cells [scored as 0 (0-5% positive), 1
(6-25%), 2 (26-50%), 3 (51-75%), or 4 (>75%)]. A histo-
score was generated by multiplying the mean intensity
and percent scores (overall score range, 0–12). The histo-
score was then dichotomized into low expression (histo-
score, 0–6) and high expression (histoscore, 8–12). We
selected a histoscores of 8 as the cutoff point for positive
expression because histoscore of 8 or more matched with
cases with strong or moderate intensity. Additional cut-
points were not evaluated. For pERK1/2, nuclear and cyto-
plasmic staining was dichotomized into low expression
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Slides were scored without any clinical information, and
the final staining score reported was the average of two in-
dependent pathologists.
Statistical analysis
Statistical analyses of API5 and pERK1/2 expressions were
performed using the Mann–Whitney test or the Kruskal-
Wallis test. The x2-test was used to assess associations
between molecular markers. Overall and disease-free sur-
vival curves were calculated according to the Kaplan-
Meier method; survival analysis was performed using the
log-rank test. The Cox proportional hazards model was
used to estimate hazard ratios and confidence intervals
in both univariate and multivariate models. Statistical
analyses were done using SPSS version 18.0 (SPSS Inc.,
Chicago, IL). A value of P < 0.05 was considered statisti-
cally significant.
Results
Localization of API5 in cervical cancer cell lines
The expression of human API5 was investigated in human
cervical cancer cell lines using western blot analysis. HEK
293 human embryonic kidney epithelial cells were used asA
GAPDH
API5
C DAPIDIC
Figure 1 API5 expression and its localization in various cervical cance
cancer cell lines by western blot analysis. (B) Nuclear and cytoplasmic fract
and Lamin B1 were used as an index for cytosolic or nuclear fraction, respe
evaluate the distribution of API5 in HeLa cells 24 hrs after transfection of pE
Magnified images of boxed areas are shown in the lower panels. Arrowheaa control cell line representing non-tumorigenic cells. As
shown in Figure 1A, API5 was detected as doublet bands,
as has been reported in mammals [13]. Expression of
API5 was most profound in HeLa and C33A while that in
CaSki and SiHa was similar to non-turmorigenic HEK293
cells. We further analyzed the expression of API5 protein
in cytoplasmic and nuclear fractions of the HeLa cells
which have the highest expression of API5 among the cer-
vical cancer cell lines examined by western blot analysis.
As shown in Figure 1B, API5 was exclusively detected
in the nuclear fraction. To further confirm the nuclear/
cytosolic localization of API5, HeLa cells were trans-
fected with pEGFP-Api5 DNA, and, in turn, examined
with confocal laser scanning microscopy after counter-
staining nuclear with DAPI. As shown in Figure 1C, we
observed the dominant localization of API5 in nucleus
although cytoplasmic API5 (indicated by arrowheads)
was observed in small population of the transfected
HeLa cells (less than 8%). We also observed a similar
localization pattern of endogenous API5 in CaSki cells
after immunofluorescence staining (Additional file 1:
Figure S1). Taken together, these results demonstrate
that API5 expresses in cervical cancer cell lines and is
primarily localized in nucleus.B
API5
Calnexin
C        N
HeLa
Lamin B1
EGFP-API5 MERGE
r cell lines. (A) Characterization of API5 expression in various cervical
ions from HeLa cells were analyzed by western blot analysis. Calnexin
ctively. (C) Confocal fluorescent microscopy was used to further
GFP-API5. DAPI fluorescent dye was used for a nuclear counterstaining.
ds indicate cytoplasmic EGFP-API5 in the transfected HeLa cells.
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in cervical cancer cell lines
To evaluate the effects of API5 on cell proliferation, the
API5 expression vector or the control vector (no insert)
were transfected into CaSki cells which have a low level
of API5 expression. Non-tumorigenic HEK 293 cells
with low background of API5 expression level were used
as a positive control for comparison. Conversely, siRNA
targeting API5 (siAPI5) or GFP (irrelevant negative con-
trol, siGFP) were also transfected into HeLa cells which
have a high level of API5 expression. API5 expression
level in the transfected cells were detected by western
blotting (Figure 2A). The cell growth assay revealed that
cell growth rate in both of the API5-transfected cells
was significantly higher than control groups (Figure 2B).
Similar increase was also observed in colony formation
assay (Figure 2C). In contrast, knock-down of API5 in
HeLa cells significantly decreased both of the cell growth
rate and colony formation efficacy compared with siGFP
control group (Figure 2B and C). These data demonstrateA
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Figure 2 API5 role in cell proliferation and colony formation of HEK29
analyzed by western blot. (B) Proliferation assay: 2 × 104 cells were plated i
by trypsinization at the indicated times, and live cells were counted after tr
500 cells were plated in 6 well plates and cultured for 2 weeks and formed
m. from one representative experiment performed in triplicate.that API5 has a key role in cell proliferation and colony
formation of cervical cancer cells.Clinicopathologic characteristics, API5 and pERK1/2
expression
To determine whether API5 overexpression is linked to
clinical features of cervical cancer, we performed immu-
nohistochemistry in a cohort of cervical tissues from pa-
tients with CIN or invasive cervical cancer. Patient ages
ranged from 19 to 83 years (mean, 42.5 years). The clin-
icopathologic characteristics of the study are summa-
rized in Additional file 2: Table S1. Tumor sizes ranged
from 0.3 to 12.3 cm (mean 2.8 cm). The following histo-
logic types were subjected: 141 squamous cell carcinomas
(81.5%), 26 adenocarcinomas/adenosquamous carcinomas
(15.0%), 5 small cell carcinomas (2.9%), and 1 clear cell
carcinoma (0.6%). HC2-based HPV infection rate was
81.1% (55/67) in low grade CIN, 90.2% (157/174) in high
grade CIN. The length of patient follow-up time ranged4 6
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follow-up was 40.5 months.
The TMA contains 173 cases of cervical cancer, however
due to the complexity of sectioning, staining, as well as
heterogeneity of the samples, only 152 and 150 samples
could be interpreted for the API5 and pERK1/2, respect-
ively. API5 protein expression was exclusively identified in
the nucleus of tumor cells while the expression of pERK1/
2 was detected in the cytoplasmic and nuclear of the tumor
cells (Figure 3A). The expressions of API5 and pERK1/2 in
relation to clinicopathologic characteristics were evaluated
(Table 1). API5 expression gradually increased according
to the phases of cervical cancer progression, from normal
tissues through low and high grade CINs to cervical can-
cers (P < 0.001). Also, it correlated with features associated
with advanced disease and poor outcome including FIGO
stage (P = 0.004), tumor grade (P < 0.001), and chemo-
radiation response (P = 0.004) (Figure 3B). In addition, sub-
group analysis by stage was conducted for various stages of
cervical cancer (Additional file 2: Table S2). The results
were similar in all subgroups according to disease severity.
The expression of pERK1/2 was up-regulated in high gradeA
P<0.001
P=0.693
P<0.001
P<0.001 P<0.001
P<0.001
B
API5
Normal Low grade CI
pERK1/2
Figure 3 API5 and pERK1/2 expression in human cervical neoplasias s
of API5 and pERK1/2 in normal, low grade CIN, high grade CIN, and cervica
neoplasia samples. API5 IHC staining score in cervical cancer samples was s
associated directly with each tumor stage, stage I tumors stained more we
poorly differentiated cervical cancer samples was significantly higher than tCIN and cancer specimens compared to normal and low
grade CIN (P < 0.001, Table 1).
Prognostic significance and association of API5 and
pERK1/2 expression
Base on the fact that API5 is overexpressed, we examined
the association between expression of API5 and pERK1/2
in cervical cancer or CIN specimens. Notably, expression
of API5 was positively associated with the expression of
pERK1/2 in both cancer (P < 0.001) and high grade CIN
specimens (P = 0.031) (Table 2). However, there is no asso-
ciation between these two protein expressions in low
grade CIN specimens. This data suggests that the expres-
sion of API5 and pERK1/2 is a closely coordinated event
in incipient cervical cancer.
We next examined the relationship of API5 expression to
patient outcome. As shown in Figure 4, Kaplan-Meier plots
demonstrated that patients with high API5 expression
(IHC score of ≥ 8) displayed significantly shorter disease-
free survival (mean of 41.5 versus 53.0 months, P = 0.001)
and overall survival (mean of 48.8 versus 58.4 months, P <
0.001) (Figure 4A and C). The high pERK1/2 expressionP=0.045
P=0.017
P=0.341 P<0.001
N High grade CIN Cancer
pecimens. (A) Representative immunohistochemical staining images
l cancer tissues. Bars: 100 μm. (B) API5 IHC staining score in cervical
ignificantly higher than that of all other groups. The mean API5 score
akly than stage II and stage IV tumors. API5 IHC staining score in
hat of well/moderately differentiated cancers.
Table 1 Expression of API5 and pERK1/2 in relation to clinicopathologic characteristics in IHC analysis
API5 pERK1/2
No. % Mean scores (95% CI) P value No. % Mean scores (95% CI) P value
All study subjects 850 100 3.53 (3.35-3.71) 793 100 2.45 (2.27-2.63)
Diagnostic category <0.001 <0.001
Normal 411 48.3 2.44 (2.23-2.65) 382 48.1 1.69 (1.54-1.85)
Low grade CIN 67 7.9 3.79 (3.23-4.36) 57 7.2 2.65 (2.17-3.13)
High grade CIN 220 25.9 4.19 (3.88-4.50) 204 25.7 3.32 (2.95-3.69)
Cancer 152 17.9 5.39 (4.92-5.87) 150 19.0 3.13 (2.53-3.73)
FIGO stage 0.004 0.205
I 102 67.1 4.88 (4.35-5.42) 99 66.0 2.89 (2.16-3.62)
II 41 27.0 6.17 (5.14-7.20) 44 29.3 3.30 (2.19-4.40)
IV 9 5.9 7.67 (5.39-9.94) 7 4.7 5.43 (1.06-9.79)
Cell type 0.533 0.114
SCC 122 80.3 5.32 (4.78-5.86) 124 82.7 3.35 (2.65-4.04)
Others 30 19.7 5.70 (4.58-6.82) 26 17.3 2.08 (1.09-3.07)
Tumor grade <0.001 0.237
Well + Moderate 94 64.4 4.69 (4.12-5.26) 96 65.3 2.78 (2.07-3.49)
Poor 52 35.6 6.62 (5.80-7.44) 51 34.7 3.53 (2.44-4.62)
Tumor size 0.932 0.776
≤ 4 cm 105 69.1 5.38 (4.82-5.94) 103 68.7 3.07 (2.37-3.77)
> 4 cm 47 30.9 5.43 (4.47-6.38) 47 31.3 3.26 (2.07-4.44)
LN metastasis 0.385 0.637
No 104 76.5 5.00 (4.45-5.55) 102 75.0 2.71 (2.02-3.40)
Yes 32 23.5 5.53 (4.24-6.82) 34 25.0 2.38 (1.25-3.52)
Chemoradiation 0.004 0.216
Good response 29 80.6 3.41 (2.27-4.56) 31 81.6 1.39 (0.66-2.11)
Bad response 7 19.4 7.00 (5.81-8.19) 7 18.4 0.43 (−0.07-0.92)
HPV test in CIN 0.951 0.940
Negative 28 12.4 4.14 (3.19-5.10) 28 13.7 3.07 (2.12-4.02)
Positive 198 87.6 4.17 (3.85-4.49) 177 86.3 3.11 (2.76-3.45)
CIN, cervical intraepithelial neoplasia; FIGO, International Federation of Gynecology and Obstetrics; SCC, squamous cell carcinoma; LN, lymph node; HPV,
human papillomavirus.
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low pERK1/2 expression group had longer survival in over-
all survival analysis (mean of 52.3 versus 56.7 months, P =
0.040) (Figure 4E). Furthermore, the patients with com-
bined high API5 and high pERK1/2 expression showed sig-
nificantly shorter disease-free survival (mean of 33.2 versus
52.2 months, P < 0.001) and overall survival (mean of 44.4
versus 58.6 months, P < 0.001) than patients who were low
API5 and low pERK1/2 expression (Figure 4C and F). The
independent prognostic significance of high API5 ex-
pression and a combined high API5 and high pERK1/2
expression as well as other clinicopathologic parameters
was determined by applying Cox proportional hazards
model. FIGO stage (P = 0.001), LN metastasis (P = 0.047),
high API5 expression (P = 0.031), and a combination ofhigh API5 and high pERK1/2 expression (P = 0.007) were
related to shorter disease-free survival (Table 3). Further-
more, SCC cell type [hazard ratio = 0.23 (95% CI, 0.06-
0.80), P = 0.021], LN metastasis [hazard ratio = 3.85 (95%
CI, 1.08-13.73), P = 0.038], high API5 expression [hazard ra-
tio = 3.98 (95% CI, 1.07-14.85), P = 0.039], and a combin-
ation of high API5 and high pERK1/2 expression [hazard
ratio = 4.14 (95% CI, 1.12-15.21), P = 0.032] were the inde-
pendent prognostic factors with respect to overall survival.
Altogether, these data indicated that API5 expression serves
as an important prognostic factor in human cervical cancer.
Discussion
API5 was originally identified as an apoptosis inhibitory
protein whose expression prevents apoptosis after growth
Figure 4 Kaplan–Meier plots of disease-free survival (A - C) and overa
expression, and co-expression of API5/pERK1/2. High API5 expression a
survival rate (D, P = 0.001). Patients with high pERK1/2 expression displaye
pERK1/2 with disease-free survival (C) and overall survival (F) was significan
Table 2 Association of API5 and pERK1/2 expression in
cervical cancer and CIN patients
API5 expression
Low (−) % High (+) % Total no. P value
Cancer 85 65.9 44 34.1 129 P < 0.001
pERK1/2 (−) 69 75.8 22 24.2 91
pERK1/2 (+) 16 42.1 22 57.9 38
High grade CIN 170 89.9 19 10.1 189 P = 0.031
pERK1/2 (−) 106 93.8 7 6.2 113
pERK1/2 (+) 64 84.2 12 15.8 76
Low grade CIN 51 96.2 2 3.8 53 P = 0.301
pERK1/2 (−) 33 94.3 2 5.7 35
pERK1/2 (+) 18 100.0 0 0.0 66
API5+, IHC score of ≥ 8; pERK1/2+, IHC score of ≥ 4.
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http://www.biomedcentral.com/1471-2407/14/545factor deprivation [10]. Recently, few studies have ad-
dressed the API5 mechanism other than its anti-apoptotic
effects [14,15,20]. The putative oncogenic role of API5
was suggested by Kim and colleagues in cervical cancer
cell lines [20]. They reported that API5 overexpression
could promote cell growth and invasiveness of cervical
cancer cell line CUMC-6 [20]. However they did not
clearly rule out the effect of endogenous API5 expression
without the application of API5 gene knockdown or silen-
cing. In this study, API5 protein levels were examined by
fractionated immunoblotting in HeLa and CaSki cervical
cell lines. API5 protein was predominantly expressed in
nuclear fraction of HeLa compared to CaSki, even without
apoptotic stimuli (Figure 1). To investigate the role of
API5 on cell growth and clonogenicity, API5 protein was
overexpressed using a wild type API5 expression vector in
CaSki as well as in non-tumorigenic HEK 293 cells. Over-
expressed API5 mediated an increase of cell proliferation
in CaSki cell line. On the other hand, inhibition of API5
expression by API5 siRNA gene knockdown resulted in
significant inhibition of cell growth in HeLa cells. Thesell survival (D - F) categorized based on API5 expression, pERK1/2
ssociated with short disease-free survival (A, P = 0.001) and overall
d worse overall survival (E, P = 0.040). The association of high API5/
tly different from that of low API5/pERK1/2 (P < 0.001 for both).
Table 3 Univariate and multivariate analyses of the associations between prognostic variables and overall survival in
173 cases of cervical cancer
Variables Overall survival hazard ratio [95% CI], P value Disease-free survival hazard ratio [95% CI], P value
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
FIGO stage (≥IIb) 3.10 [1.19-8.07], 0.020 1.62 [0.32-8.15], 0.557 5.74 [2.89-11.41], <0.001 5.86 [2.00-17.18], 0.001
Cell type (SCC) 0.30 [0.11-0.79], 0.015 0.23 [0.06-0.80], 0.021 0.84 [0.36-1.94], 0.695 NS
Tumor grade (poor) 2.75 [1.05-7.25], 0.040 1.80 [0.52-6.25], 0.353 2.09 [1.06-4.10], 0.031 1.05 [0.44-2.51], 0.901
Tumor size (>4 cm) 1.71 [0.65-4.51], 0.273 NS 2.54 [1.29-4.97], 0.007 1.28 [0.54-3.00], 0.568
LN metastasis 6.30 [2.10-18.87], 0.001 3.85 [1.08-13.73], 0.038 5.15 [2.38-11.13], <0.001 2.49 [1.02-6.17], 0.047
API5+ (≥8) 5.74 [1.82-18.05], 0.003 3.98 [1.07-14.85], 0.039 3.10 [1.52-6.34], 0.002 2.74 [1.09-6.85], 0.031
pERK1/2+ (≥4) 2.69 [1.00-7.23], 0.049 2.33 [0.65-8.32], 0.193 1.74 [0.86-3.51], 0.117 NS
API5+/pERK1/2+ 5.02 [1.91-13.22], 0.001 4.14 [1.12-15.21], 0.032 4.56 [2.25-9.24], <0.001 3.99 [1.47-10.87], 0.007
FIGO, International Federation of Gynecology and Obstetrics; SCC, squamous cell carcinoma; LN, lymph node; NS, not significant.
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linked to cancer cell proliferation, suggesting that API5
cloud contributes to the development of cervical cancer.
Epidermal Growth Factor (EGF), Insulin Growth Fac-
tor 1 (IGF-1) and Vascular Endothelial Growth Factor
(VEGF) are known to regulate cervical cancer cell prolif-
eration and invasiveness which play key roles in deter-
mining the high-risk factors and lead to recurrence and
mortality [21]. The expression of growth factor receptor
is also increased in cervical cancer tissues and cancer
cells. EGF Receptor (EGFR) is related to HPV infection
as EGFR cytoplasmic expression increases with increas-
ing grade of CIN [22]. IGF-1 receptor (IGF-1R) expres-
sion level is elevated in cervical cancer cell cultures [23].
However, the clinical utility of EGFR expression as a bio-
marker for prognosis or for treatment of cervical cancer
is not defined, as normal cervical epithelium also ex-
presses EGFR at various levels [24], and this expression
is not correlated with the HPV type [22]. The correlation
between IGF-1R expression and cervical cancer stages is
also limited in early-stage cervical cancer [25]. Thus,
several studies have been focusing on signaling pathway,
which can be activated by growth factors. Activation of
ERK/MAPK cascade by growth factors has been re-
ported in many human carcinomas, including cervical
cancer cell lines [26-29]. One critical down-stream mol-
ecule is phosphorylated ERK1/2 [30-32]. Previous studies
suggested a relationship between API5 and growth fac-
tors, such as Fibroblast Growth Factor (FGF) [13,14],
which can activate ERK/MAPK signaling cascade. Fur-
thermore, we recently demonstrated that API5 activates
ERK through FGF/FGFR1 pathway [16]. In agreement
with this study, we observed that API5 expression levels
were positively associated with ERK1/2 phosphorylation
both in high grade CIN and cancer specimens. In
addition, API5 expression positively correlated with dis-
ease severity in cervical neoplasias and negatively with
overall survival of cervical cancer patients. Taken together,our data suggest that API5 may play an important role in
the progression of cervical neoplasia through ERK/MAPK
activation.
As an anti-apoptotic protein, API5 may be closely im-
plicated in the regulation of apoptosis and is highlighted
as a potential drug target in cancer. In this context,
API5 expression has been reported in a number of
tumor cell lines [20], and, subsequently, API5 elevated
mRNA and protein expression levels were confirmed in
a wide variety of transformed cell lines [11,13,20,33,34].
Sasaki and colleagues reported that an increased API5
mRNA expression was detected in 12.7% (12/94) of the
non-small cell lung cancer (NSCLC) biopsies and its
presence was correlated with poor survival, especially in
patients with squamous cell lung cancer [15]. Likewise,
Wang et al. investigated the prognosis characteristics of
API5 and used real-time RT-PCR to characterize API5,
casein kinase 2 α subunit (CSNK2A1), and NME1 tran-
scripts in 145 NSCLC cases [35]. They showed that a
combination of high CSNK2A1 and high API5 mRNA
expressions was predictive of poor prognosis in NSCLC
patients [35]. Kim et al. previously reported API5 gene
up-regulation in some metastatic lesions in lymph node
tissues and did not find API5 overexpression in primary
cervical cancer tissues, due to the small number of ex-
amined cases [20]. In spite of supporting evidence of
API5 gene involvement in tumorigenesis, the informa-
tion about its protein expression in human tumors is
still scarce. Recently, Koci and colleagues analyzed API5
protein expression in a variety of human carcinomas by
western blotting [36]. They detected API5 protein ex-
pression in biopsies of lung (23%, 3/13) and colorectal
tumors (33%, 9/27). In the current study, we observed
increased protein expression of API5 in 34.2% (52/152
cases) of cervical cancers, and API5 expression level
gradually increased during the transition from normal
tissue to cervical carcinoma (Table 1), suggesting an im-
portant role of API5 in cervical tumor progression.
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higher API5 protein expression in poorly differentiated
carcinomas (mean score = 6.62) than in well and moder-
ately differentiated carcinomas (mean score = 4.69). It is
reasonable to deduce that up-regulated API5 expression
was more frequent in poorly differentiated carcinomas
as API5 putative invasiveness has been reported in cer-
vical cancer cell lines [20]. In addition, API5 expression
positively correlated with cervical cancers resistance to
chemo-radiation therapy. These data underscore the
value of API5 expression as a high risk factor in cervical
cancer. Clinically, concurrent platinum-based chemo-
radiation has become the mainstay for treating locally
advanced cervical cancers. Although chemo-radiation
has significantly improved both disease-free and overall
survival of cervical cancer patients when compared to
radiation alone, the 5-year overall survival of patients
treated primarily with combination therapy is still under
70% [2]. Currently, no known molecular marker can ac-
curately predict the response to platinum-based chemo-
radiation or outcome in cervical cancer. However, we
showed that API5 expression in cervical cancer speci-
mens positively correlated with resistance to chemo-
radiation therapy, implicating API5 overexpression as a
strong risk factor for poor outcomes in cervical cancer.
Thus, our study suggests the possibility that the effect of
chemo-radiation can be compromised in cervical cancer
patients with API5 overexpression, an observation that
can have profound clinical implications. Further research
regarding the molecular mechanisms responsible for
API5-associated resistance to chemo-radiation will hope-
fully provide new insights, allowing the identification of
new potential targets for therapy and the design of bet-
ter treatment strategies. Although there was a small in-
crease in API5 expression in LN metastasis cases, when
compared with those without, we did not find a correl-
ation between API5 expression and the presence of LN
metastasis. This may be due to the smaller sample size
of LN metastasis cases (n = 37) when compared to that
of no metastasis (n = 119). We also included HPV infec-
tion in the analysis and observed no statistical difference
in API5 expression between HPV-positive (n = 198) and
-negative (n = 28) patients. Therefore, further studies are
needed to establish the relationship between API5 and
the aggressiveness of cervical cancer cells, and to identify
the exact causation of API5 overexpression in cervical
cancer.
Our study also showed that API5 expression in cervical
cancer was associated with poor overall and disease-free
survival. Patients with high levels of API5 expression had
an increased risk of disease progression and death. In
addition, API5 expression was an independent prognostic
factor for overall and disease-free survival after adjusting
for well-known prognostic parameters including FIGOstage, cell type, tumor grade, tumor size and LN metasta-
sis. In agreement with our study, poor prognosis has been
reported in a study of 94 NSCLC patients with increased
API5 expression [15]. To the best of our knowledge, this is
the first study designed to evaluate the association be-
tween API5 expression and clinicopathologic variables, in-
cluding survival of cervical cancer patients. Our results
not only suggest the promising potential of API5 as a
prognostic and survival marker, but also warrant further
studies on a possible link between the biological function
of API5 and the pathogenesis of cervical cancer.
Conclusions
In conclusion, we demonstrated that API5 plays a key
role in cell proliferation and colony formation. Subse-
quently, we observed that API5 protein is overexpressed
in human cervical cancer tissue specimens. API5 protein
expression levels were found to significantly correlate
with the prognosis of cervical cancer, as high level of
API5 protein expression in cervical cancer lesions is
closely associated with advanced tumor stage and grade,
and shorter overall survival for the patients. Overall, our
study suggests that overexpression of API5 is a common
features in cervical cancer and might represent a novel
prognostic marker for the disease.
Additional files
Additional file 1: Figure S1. Localization of endogenous API5 in CaSki
cells. Confocal fluorescent microscopy was used to evaluate the
distribution of endogenous API5 in CaSki cells. The cells were fixed,
permeabilized, and then immunostained with anti-API5 antibody (Santa
Cruz, USA; H-300, 1: 250) at 4°C for overnight. After washing with PBS, the
cells were further incubated with Alexa Flour 488-conjugated goat
anti-rabbit IgG (Invitrogen) for 1 hr at room temperature, followed by
washing with PBS, and then analyzed using a Confocal fluorescent
microscopy. DAPI fluorescent dye was used for a nuclear counterstaining.
Additional file 2: Table S1. Clinicopathologic characteristics of cases.
Table S2. API5 expression in various stages of cervical cancer.
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